Cargando…

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467589/ https://www.ncbi.nlm.nih.gov/pubmed/32905262 http://dx.doi.org/10.1093/ckj/sfz009

Ejemplares similares

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: Reith, C., et al.
Publicado: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2020)

Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
por: Kaul, Sanjay
Publicado: (2018)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Publicado: (2022)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Anti-Müllerian hormone concentrations in women with chronic kidney disease
por: Wiles, Kate, et al.
Publicado: (2020)

Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study
por: Nixon, Andrew C, et al.
Publicado: (2019)

Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study
por: Nixon, Andrew C, et al.
Publicado: (2020)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Erratum for Hypertension, retinopathy, and acute kidney injury in dogs: A prospective study
Publicado: (2020)

Prognosis and long-term outcomes of acute kidney injury due to snake envenomation
por: Priyamvada, P S, et al.
Publicado: (2020)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Erratum to: COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
por: Hilbrands, Luuk B, et al.
Publicado: (2021)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2noia6jld4i78hh683lct2b4tr